State Street Corp Cuts Stake in LivaNova PLC (NASDAQ:LIVN)

State Street Corp lessened its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 0.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,039,260 shares of the company's stock after selling 10,785 shares during the quarter. State Street Corp owned approximately 3.76% of LivaNova worth $107,143,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Point72 Asset Management L.P. boosted its holdings in LivaNova by 204.3% during the second quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company's stock worth $70,479,000 after purchasing an additional 863,157 shares during the last quarter. First Light Asset Management LLC boosted its position in LivaNova by 591.1% in the second quarter. First Light Asset Management LLC now owns 710,390 shares of the company's stock worth $38,944,000 after purchasing an additional 607,598 shares during the last quarter. Great Lakes Advisors LLC bought a new position in LivaNova in the 2nd quarter valued at $16,614,000. Driehaus Capital Management LLC grew its stake in LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company's stock valued at $29,824,000 after purchasing an additional 213,749 shares during the period. Finally, Point72 DIFC Ltd increased its position in shares of LivaNova by 75,799.6% during the 3rd quarter. Point72 DIFC Ltd now owns 181,400 shares of the company's stock valued at $9,531,000 after purchasing an additional 181,161 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

LIVN has been the subject of a number of research analyst reports. StockNews.com downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a report on Saturday, November 16th. Needham & Company LLC reiterated a "buy" rating and issued a $75.00 price objective on shares of LivaNova in a research note on Monday, November 25th. Mizuho lowered their target price on LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, October 31st. Baird R W upgraded LivaNova from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 17th. Finally, The Goldman Sachs Group initiated coverage on LivaNova in a report on Friday, October 4th. They issued a "buy" rating and a $65.00 price objective for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, LivaNova currently has an average rating of "Buy" and an average target price of $69.17.

LivaNova Price Performance

LIVN stock traded down $1.35 during mid-day trading on Monday, reaching $50.15. 520,963 shares of the company traded hands, compared to its average volume of 609,696. The company has a fifty day moving average price of $51.97 and a 200-day moving average price of $51.43. LivaNova PLC has a 52-week low of $43.15 and a 52-week high of $64.47. The company has a market capitalization of $2.72 billion, a P/E ratio of 122.62 and a beta of 0.98. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Insider Buying and Selling

In other news, Director Francesco Bianchi sold 1,250 shares of the business's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.27% of the stock is currently owned by insiders.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.